Laddar populära aktier...
Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen
Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström
Nanoform Q3 2024 report: Record number of new projects signed
Invitation to Nanoform’s Q3 2024 Report Presentation
Disclosure as attachment of the Nanoform 2022 Report of the Board of Directors and Financial Statements which were previously linked to a Co...
Share subscriptions based on Nanoform Finland Plc’s stock options 2/2019
Nanoform and Celanese Expand Collaboration into Long-Acting Biologics Delivery Through Small Implants
Nanoform Q2 report: All business targets for 2024 on track
Invitation to Nanoform’s Q2 2024 Report Presentation
NANOFORM COLLABORATES WITH TAKEDA ON THEIR PLASMA-DERIVED THERAPY DEVELOPMENT
Nanoform Finland Plc – Manager’s Transactions – Jeanne Thoma
Nanoform Finland Plc – Manager’s Transactions – Mads Laustsen
Nanoform Finland Plc – Manager’s Transactions – Miguel Calado
Share subscriptions based on the resolution by Nanoform Finland Plc’s Annual General Meeting 2024 on remuneration of the Board of Directors
Nanoform's biologics technology showcased by large pharma at drug delivery conference; Nanoenzalutamide and nanoapalutamide partnering discu...
Disclosure of Major Holdings under Law 163/2024
Invitation to Nanoform’s Q1 2024 Report Presentation
Nanoformed High-Concentration Biologics Formulation for Subcutaneous Delivery Results to be Presented by Takeda at DDF Summit
New shares of Nanoform registered with the trade register
Nanoform successfully completes new share issue raising EUR 15.
Nanoform announces its intention to carry out a new share issue of approximately 7 million new shares to invest in commercialization of nano...
Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc
Resolutions of Nanoform Finland Plc's Annual General Meeting on April 16, 2024
Nanoform Enters Exclusive Partnership with CBC to Bring Best-in-Class Nanomedicine Technology to Japan
Nanoform and PlusVitech partner to repurpose aprepitant as a treatment for lung cancer
Nanoform Finland Plc: Certified Adviser change to Carnegie Investment Bank Ab
The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key individuals
Notice to the Annual General Meeting of NANOFORM FINLAND Plc
Share subscriptions based on Nanoform Finland Plc’s stock options 2/2019 and 1/2020
Nanoform Finland Plc – Manager’s transactions – Albert Hæggström
Nanoform Finland Plc – Manager’s transactions – Jeanne Thoma
Nanoform Finland Plc – Manager’s transactions – Mads Laustsen
Nanoform Finland Plc – Manager’s transactions – Miguel Calado
Apalutamide Study Again Demonstrates the Advantages of Nanoforming Over Traditional Cancer Treatment Formulations
Strong momentum in Project Nanoenzalutamide
Invitation to Nanoform’s Q4 and FY 2023 Report Presentation
Inside information made public: Nanoform Wins R&D Grant of EUR 4.
Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-En...
Nanoform Finland Plc – Manager’s transactions – Antonio Da Silva
Nanoform Finland Plc – Manager’s transactions – Johanna Kause
Nanoform Finland Plc – Manager’s transactions – Christian Jones
Nanoform Finland Plc – Manager’s transactions – Peter Hänninen
Nanoform Finland Plc – Manager’s transactions – Edward Hæggström
Nanoform Finland Plc – Manager’s transactions – David Rowe
The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
Correction: Share subscriptions based on Nanoform Finland Plc’s stock options 1/2020 and 2/2019
Share subscriptions based on Nanoform Finland Plc’s stock options 1/2019 and 2/2019
Nanoform Q3 2023: Nanoformed blockbuster drug enters clinic and another nanoformed drug received FDA orphan designation
Invitation to Nanoform’s Q3 2023 Interim Report
Nanoform grant Global STARMAP[®] AI License to AstraZeneca
Nanoformed TargTex oncology drug candidate TTX101 receives FDA Orphan Drug Designation
Nanoform Finland Plc – Managers’ transactions – David Rowe
Nanoform Finland Plc – Managers’ transactions – Johanna Kause
Nanoform Finland Plc – Managers’ transactions – Peter Hänninen
Nanoform Finland Plc – Managers’ transactions – Christian Jones
Nanoform Finland Plc – Managers’ transactions – Antonio Da Silva
Nanoform Finland Plc – Managers’ transactions – Albert Hæggström
The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees
Nanoform Q2 2023 – A record 11 new customer projects signed and targeting first license/commercial supply agreement in 2024
Invitation to Nanoform’s Q2 2023 Interim Report
Nanoform and Celanese Demonstrate Enhanced Drug Delivery through the Power of Smaller Implants
Nanoform Q1 2023 interim report – A strong start to the new year
Invitation to Nanoform’s Q1 2023 Interim Report
FIMEA renews Nanoform’s GMP license and Nanoform starts clinical API manufacturing of a blockbuster medicine candidate
Share subscriptions based on Nanoform Finland Plc’s stock options 3-5/2019 and 1/2020
Resolutions of Nanoform Finland Plc's Annual General Meeting on April 12, 2023
Nanoform reports continued progress in 2022 and sets new targets for 2023
Invitation to Nanoform Q4 and FY2022 report
Nanoform Finland Plc – Manager’s transactions – Antonio da Silva
Nanoform appoints Antonio da Silva as Chief of Business Operations (CBO) and member of the Management Team
Nanoform CTO Niklas Sandler transitions to technology advisor to the CEO
Nanoform financial calendar for 2023
Nanoform Q3 and 9M 2022 report: Continued solid progress
Invitation to Nanoform’s Interim Report January-September 2022
Nanoform Finland Plc – Manager’s transactions – Niklas Sandler
TargTex to present Tumour Eradication in Rodents from its Nanoformed Glioblastoma drug
Share subscriptions based on Nanoform Finland Plc’s stock options 2-3/2019 and 1/2020
Nanoform Q2 and H1 2022 report: Strong momentum continues
Invitation to Nanoform’s Interim Report January-June 2022
